AstraZeneca settles Crestor patent row with generics firms

LONDON, March 25 Mon Mar 25, 2013 3:16am EDT

LONDON, March 25 (Reuters) - AstraZeneca has settled a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in the all-important U.S. market until 2016.

Under the agreement, Watson and Egis concede that the Crestor substance patent is valid. The settlement allows Watson to begin selling a generic version of Crestor on May 2, 2016, at a fee to AstraZeneca of 39 percent of net sales, until the end of paediatric exclusivity on July 8, 2016.

AstraZeneca said on Monday its partner Shionogi was also a party to the settlement agreement.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.